XAV19
Viral Infections
PreclinicalActive
Key Facts
About Xenothera
Xenothera is a clinical-stage biotech with a unique focus on engineering polyclonal antibodies. Its core technology, glyco-humanization (GH), removes non-human sugar antigens from antibodies derived from animals, aiming to create multispecific, low-immunogenicity therapies. The company has built an active pipeline targeting solid tumors, T-cell lymphomas, and infectious diseases, with its lead oncology candidate, XON7, already in clinical trials since 2023. Backed by a seasoned leadership team and strategic collaborations, Xenothera is positioning itself as an innovator in complex antibody therapeutics.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Pre-clinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Anti-Viral Program | MicroQuin | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |